<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Use of <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) may reduce the incidence of several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A recent meta-analysis of randomized trials of aspirin reported a reduction in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality; however, few studies have investigated whether aspirin or other <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> reduce overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: 64,847 residents of western Washington State, aged 50-76, completed a baseline questionnaire in 2000-2002 and reported on their use of individual <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> over the past 10 years </plain></SENT>
<SENT sid="3" pm="."><plain>Behavior was categorized as non-use, low (&lt;4 days/week or &lt;4 years), and high (≥4 days/week and ≥4 years) </plain></SENT>
<SENT sid="4" pm="."><plain>Over 7 years of follow-up, 5,946 incident <z:e sem="disease" ids="C0677898" disease_type="Neoplastic Process" abbrv="">invasive cancer</z:e> cases were identified </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariable proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Relative to non-use, high 10-year use of regular-strength <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> was inversely associated with total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in men (HR 0.88, 95% CI: 0.79-0.97) and not associated with risk in women (HR 1.10, 95% CI: 0.96-1.25; p interaction &lt;0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Use of regular-strength <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> was strongly and inversely associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk in men and women, but differentially associated with sex-specific risk of shared <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> sites other than <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (men: HR 0.83, 95% CI: 0.71-0.97; women: HR 1.18, 95% CI: 0.97-1.44; p interaction &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Long-term use of <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> was associated with a reduced risk of total <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> among men and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> among both sexes </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings do not support <z:chebi fb="1" ids="35475">NSAID</z:chebi> use for overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention among women </plain></SENT>
<SENT sid="10" pm="."><plain>Additional high-quality studies with long-term follow-up for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> among women are needed before a public health recommendation can be made </plain></SENT>
</text></document>